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Abstract
MKR mice, lacking insulin-like growth factor 1 receptor (IGF-1R) signaling in skeletal muscle, are lean yet hyperlipidemic,
hyperinsulinemic, and hyperglycemic, with severe insulin resistance and elevated hepatic and skeletal muscle levels of
triglycerides. We have previously shown that chronic peripheral administration of the adipokine leptin improves hepatic
insulin sensitivity in these mice independently of its effects on food intake. As central leptin signaling has been implicated in
the control of peripheral glucose homeostasis, here we examined the ability of central intracerebroventricular leptin
administration to affect energy balance and peripheral glucose homeostasis in non-obese diabetic male MKR mice. Central
leptin significantly reduced food intake, body weight gain and adiposity, as well as serum glucose, insulin, leptin, free fatty
acid and triglyceride levels relative to ACSF treated controls. These reductions were accompanied by increased fat oxidation
as measured by indirect calorimetry, as well as increased oxygen consumption. Central leptin also improved glucose
tolerance and hepatic insulin sensitivity determined using the euglycemic-hyperinsulinemic clamps relative to pair fed
vehicle treated controls, as well as increasing the rate of glucose disappearance. Hepatic vagotomy only partially reversed
the ability of central leptin to improve glucose tolerance. These results demonstrate that central leptin dramatically
improves insulin sensitivity independently of its effects on food intake, in a lean mouse model of type 2 diabetes. The
findings also suggest that: 1) both hepatic vagal and non-vagal pathways contribute to this improvement, and 2) central
leptin alters glucose disposal in skeletal muscle in this model.
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Introduction
MKR mice are a model of non-obese Type 2 diabetes created
by engineering a muscle-specific dominant-negative insulin-like
growth factor-1 receptor (IGF-1R) transgene that abrogates IGF-
1R and insulin receptor (IR) function in skeletal muscle by forming
hybrids exclusively with endogenous muscle IGF-1Rs [1]. The
formation of similar hybrids with endogenous insulin receptors
similarly inhibits their function by greater than 80%. As a
consequence, MKR mice are born with severe muscle insulin
resistance and subsequently develop insulin resistance in both liver
and adipose tissue. Eventually b cell dysfunction occurs, as
demonstrated by a loss of first phase insulin secretion, but with an
exaggerated second phase insulin secretion. Thus, by 6–8 weeks of
age, MKR mice characteristically demonstrate hyperinsulinemia,
hyperglycemia, hyperlipidemia and increased tissue TG levels [2].
Results from our previous studies suggested that the rapid
progression of MKR phenotype from pre-diabetic levels to frank
diabetes is secondary to their hyperlipidemia and increased TG levels
inmuscleandliver.Accordingly,chronicperipheraladministrationof
b adrenergic agonists or fibrates to MKR mice reduced tissue lipid
levels and improved hepatic insulin sensitivity [3]. We subsequently
found that chronic peripheral administration of the adipokine leptin
to MKR mice also dramatically reduced adiposity, increased fat
oxidation, and improved hepatic insulin sensitivity and glucose
homeostasis, independently of its effects on food intake [4]. The sites
and modes of leptin action responsible for these improvements
remainunknown,butmayinvolvethecentralnervoussystem;central
leptin receptor signaling has been implicated in the control of
multiple determinants of peripheral glucose homeostasis, including
fatty acid oxidation, lipogenesis [5], hepatic insulin resistance [6],
hepatic glucose fluxes [7], and skeletal muscle substrate utilization
[8,9]. Consequently, the present studies were designed to determine
whether central leptin administration would be sufficient to
recapitulate the beneficial metabolic effects of peripheral leptin in
the lean Type 2 diabetic MKR mouse. As the hepatic vagus has also
been implicated in the central leptinergic control of glucose
homeostasis [10], we also examined whether the hepatic vagus
mediated any effects of central leptin on glucose tolerance.
Materials and Methods
Animals
MKR Type 2 diabetic mice have been previously described [1].
Male MKR mice on an FVBn background were studied in these
experiments. Homozygous MKR mice were identified by tail-vein
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weeks post-weaning, compared with WT mice with normal blood
glucose levels (between 150–180 mg/dl). Throughout all studies,
mice were maintained in a 12-h light/dark cycle and were fed
standard NIH -07 diet with ad libitum access to tap water. All
animal protocols were approved by the IACUC committees of the
Mount Sinai School of Medicine and the Albert Einstein College
of Medicine of Yeshiva University.
Surgical Procedures
Third ventricle cannulation. Under i.p ketamine/xylazine
anesthesia (Ketamine (100 mg/kg) and Xylazine (10 mg/kg) [11],
10–12 wk old MKR mice were stereotaxically implanted with a 28
G chronic stainless steel cannula (Plastics One Inc.) targeting the
3
rd ventricle (coordinates: A/P 21.6 mm posterior to bregma, D/
V 24.7 mm). After a 1 week recovery period, mice were briefly
anesthetized under 0.25% isoflurane, and an Alzet 1004
minipump (Cupertine, CA) was inserted subcutaneously on the
back and connected to the 3
rd ventricle cannula via a polyethylene
tubing connector kit (Alzet). Pumps were preloaded with either
recombinant mouse leptin (R&D systems, Minneapolis, MN)
dissolved in artificial cerebrospinal fluid (ACSF) or ACSF
(Harvard Apparatus, Boston, MA). Infusion rate and duration
was 0.25 ul/hour (leptin: 0.0417 ug/hour) for 5–14 days,
depending on the study. Accurate 3rd ventricle cannula
placement was confirmed by postmortem inspection of the
cerebroventricular spread of a 500 nl India ink injection.
Hepatic branch vagotomy. Hepatic branch vagotomy was
performed in Ketamine/Xylazine anesthetized animals as
previously described [10]. Briefly, a laparotomy incision was
Figure 1. Body Weight, Food Intake, And Body Composition In Leptin Treated MKR Mice. Two week third intracerebroventricular leptin
treatment (filled symbols) reduced body weight gain (A), 24 h daily food intake (B), fat mass (C) and produced a small reduction in lean mass (D) in
male MKR mice, relative to artificial cerebrospinal fluid (ACSF) vehicle treated controls (open symbols). All data presented as means 6 SEM, N=6/
group. * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0017058.g001
Figure 2. Body Weights (A) And Fat Content (B), Before And
After 14 Days Of ICV Leptin Treatment Compared With ACSF
And Pair-Fed Control Mice. All data presented as means 6 SEM,
N=6–7/group. * p,0.05. Different superscript letters indicate signifi-
cant differences at p,0.05.
doi:10.1371/journal.pone.0017058.g002
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opened, revealing the gastrointestinal tract in the peritoneum. The
gastrohepatic ligament was severed, and the stomach was gently
retracted onto sterile saline soaked cotton gauze, revealing the
descending ventral esophagus and the ventral subdiaphragmatic
vagal trunk. The hepatic branch of this vagal trunk was visua-
lized using a neurosurgical dissecting scope under 10–206
magnification, and the hepatic branch of the vagus was ligated
using two 8.0 silk ties. The hepatic nerve trunk was then transected
by microcautery between the two sutures, severing and cau-
terizing the hepatic vagus, thereby minimizing the possibility of
regeneration. The muscle and skin layers of the laparotomy
incision were closed with Prolene suture and surgical adhesive
(Vetbond), respectively. After experiments, animals were sacrificed
and the adequacy of the procedure was assessed by demonstrating
the absence of vagal nerve tissue between the sutures. For sham
surgeries, a midline laparotomy was performed and the hepatic
vagal nerve trunk ware exposed but not manipulated or severed.
Vascular catheter implantation. One week prior to clamp
studies, catheters were inserted in the right jugular vein (MRE-
025, Braintree Scientific Inc.) and carotid artery (0007700, Alzet,
Cupertino, CA) during anesthesia with 0.25% isoflurane.
Figure 3. Locomotor Activity And Metabolic Functions In Leptin Treated MKR Mice. Two week third intracerebroventricular leptin
treatment (black bars) reduced light and dark phase locomotor activity (A,B), respiratory quotient (RER, C,D) and increased both light and dark phase
oxygen consumption in male MKR mice relative to artificial cerebrospinal fluid (ACSF) vehicle treated controls (open bars) (E,F). All data presenteda s
means 6 SEM, N=6/group. * p,0.05.
doi:10.1371/journal.pone.0017058.g003
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For five days before and throughout a 14 day period of ICV
leptin or ACSF infusion, animals were individually housed in
metabolic chambers maintained at 21–22uC on a 12-hour light/12
dark cycle with lights on at 7 am, and were provided with
nutritionally complete standard powdered diet (NIH 07) and tap
water ad libitum. Metabolic and behavioral measurements
(oxygen consumption, food intake, locomotor activity) were
obtained continuously using a CLAMS (Columbus Instruments)
open-circuit indirect calorimetry system. Body weights were
measured daily, and body composition was determined weekly
by magnetic resonance spectroscopy using an ECHOMRI
instrument (Echo Medical Systems.). For pair fed groups, each
animal received food in individual cages, and the amount of food
provided was adjusted daily to correspond to the average amount
of food consumed by the leptin treated group for each successive
day of leptin treatement.
Plasma Assessments
Serum insulin and leptin levels were measured using radioim-
munoassay kits (Linco, St. Charles, MO). Serum free fatty acids
and triglyceride levels were measured by enzymatic colorimetric
assay (Roche, Penzberg, Germany and Thermo, Victoria,
Australia, respectively). Blood glucose was measured by gluc-
ometer (Analox GM 7, Analox Instruments, Lunenburg, MA).
Glucose Tolerance Tests
Two weeks following chronic 3
rd ventricle minipump implan-
tation for leptin and ACSF control infusions, i.p. glucose tolerance
tests (ipGTTs) were performed. Briefly, after a 5 hour fast, mice
were injected intraperitoneally with glucose (2 g/kg BW) and
blood glucose levels were determined from tail vein samples at 0,
15, 30, 60 and 120 minutes after the injection.
Hyperinsulinemic-Euglycemic Clamp Studies
In separate studies designed to determine the mechanisms
involved in the improvement in glucose homeostasis following 3
rd
ventricle leptin infusion, hyperglycemic–euglycemic clamps were
performed in unrestrained mice 5 days following the onset of the
central minipump infusion. Vascular catheters were inserted as
described above, 8 days prior to the clamps to allow for surgical
recovery prior to minipump implantation. Mice were fasted for
5 h prior to clamps. The clamp protocol consisted of a 90-min
tracer equilibration period (t= 290 to 0 min) beginning at 12:00
P.M. followed by a 120-min experimental period (t=0 to
120 min). A blood sample was obtained at t= 290 min to
determine initial glucose levels. A 5-uCi bolus of [3-3H] glucose
purified by high-performance liquid chromatography was given at
t= 290 min followed by a 0.05 uCi/min infusion. At t=215
and 25 min, a blood sample (10 ul) was taken for the assessment
of basal glucose and insulin levels and glucose turnover. The
insulin clamp was begun at t =0 min with a primed-continuous
infusion of human insulin (300 mU/kg bolus followed by 3 mU/
kg/min 1; Novolin; Novo Nordisk, Princeton, NJ). The [3-3H]
glucose infusion was increased to 0.1 uCi/min for the remainder
of the experiment. Euglycemia (120–130 mg/dl) was maintained
during clamps by measuring blood glucose every 10 min starting
at t=0 min and infusing 45% dextrose as necessary. Blood
samples (60–200 ul) were taken every 10 min from t=80
to120 min and processed to determine glucose specific activity.
Clamp insulin levels were determined from samples obtained at
t=80 and 120 min. All blood samples were resuspended in
heparinized saline and infused back to mice to maintain
hematocrit. Plasma samples were collected to determine glucose
levels and specific activities of [3-3H]-glucose. All tissue samples
were stored at 280uC for subsequent analysis.
Statistical Analyses
Statistical comparisons were made by one way, two way or
repeated measures ANOVAs, using Bonferroni correction for
planned comparisons. An alpha level of 0,0.05 indicated
significant differences among treatments. Unless otherwise spec-
ified, data are presented as means 6 SEM.
Results
Food Intake, Body Weight And Locomotor Activity
Chronic ICV leptin infusion caused a ,10–15% reduction in
body weight (BW) in MKR mice that began within 1–2 days of
infusion onset, and remained stable thereafter (Figure 1A), while
Figure 4. Glucose Tolerance Tests In Leptin And Vehicle
Treated MKR Mice. Two week intracerebroventricular leptin treat-
ment significantly improved glucose tolerance in male MKR mice
relative to artificial cerebrospinal fluid (ACSF) vehicle treated controls
and pair fed, ACSF treated MKR mice. A. Intraperitoneal glucose
tolerance test (ipGTT, 2 g/kg), B. Area under the curve (AUC) during
ipGTT. All data presented as means 6 SEM, N=6–7/group. * p,0.05,
** p,0.01.
doi:10.1371/journal.pone.0017058.g004
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accompanied at weeks 1 and 2 by significantly reduced food intake
and fat mass, a small but significant reduction in lean mass
(Figure 1B–D). Body weight and fat mass were also measured in
pair-fed controls (Figure 2 A and B) and only leptin treated mice
showed a marked decrease in fat mass. A small but significant
reduction in circulating plasma leptin levels (1.760.2 ng/ml versus
2.060.3 ng/ml, p,0.05) was seen. Central leptin treatment also
significantly reduced serum insulin, FFA and TG levels relative to
ACSF treated controls (insulin: 1.260.23 vs. 3.260.3 ng/ml; FFA:
0.35608 vs 0.75612 ng/dl, p,0.01; TG: 0.260.1 vs.
1.460.3 nM (all p,0.01)).
Spontaneous locomotor activity during both light and dark
phases was significantly reduced in ICV leptin treated MKR mice
relative to controls (Figure 3A–B). Leptin also decreased
respiratory equivalent ratio (RER) during the dark but not light
phase, demonstrating increased fat oxidation (Figure 3C–D).
These changes were accompanied by increased oxygen consump-
tion during both light and dark phases in leptin treated mice
(Figure 3E–F).
Prior to and immediately following implantation of the infusion
pumps, fed blood glucose levels remained in the diabetic range in
all MKR mice (between 300–400 mg/dl). ICV leptin significantly
lowered fasting blood glucose (BG) beginning 1 week following
leptin infusion (98.8614 mg/dl vs. 222623 mg/dl, p,0.001),
while pair feeding ACSF treated mice to the level of leptin treated
controls was without effect (ACSF: BG 222623 vs. ACSF pair fed:
BG 182613 mg/dl, N.S.). ICV leptin also significantly improved
glucose tolerance relative to both ASCF and ASCF-pair fed
controls (Figure 4A–B).
Hyperinsulinemic Euglycemic Clamp Studies
Glucose infusion rate (GIR) and the rate of glucose disappear-
ance (Rd) during hyperinsulinemic-euglycemic clamps were
significantly increased in central leptin treated-MKR mice relative
to ACSF and ACSF, pair fed mice (Figure 5 A–B). Leptin also
produced a small but significant reduction in basal glucose
production (Figure 5C). However, endogenous glucose production
during the clamp was greatly reduced in mice receiving central
leptin infusion relative to both control groups (Figure 5C). Pair
feeding alone significantly increased GIR and Rd and decreased
glucose production during the clamps, although not to the degree
elicited by central leptin infusions (Figure 5 A,B,D).
Effects Of Hepatic Branch Vagotomy
Five hr. fasted blood glucose levels were lower in all leptin
treated MKR mice compared to ACSF and ACSF pair fed
controls, but this leptin-induced reduction was unaffected by
hepatic branch vagotomy (LEPTIN + SHAM: 104 ng/dl 618 vs.
LEPTIN 6 VAGOTOMY: 109 mg/dl 613) (Figure 6A). Fol-
lowing ip glucose injection, hepatic branch vagotomized MKR
mice showed significantly less of a reduction in blood glucose levels
at 15 and 120 min, but their AUC for blood glucose did not differ
from that of sham vagotomized mice infused with leptin
(Figure 6A,B). Hepatic branch vagotomy alone failed to alter
Figure 5. Hyperinsulinemic-euglycemic clamps. Third intracerebroventricular leptin treatment (black bars) significantly improved hepatic
insulin sensitivity and glucose disposal during hyperinsulinemic-euglycemic clamps in male MKR mice relative to artificial cerebrospinal fluid (ACSF)
vehicle treated controls (open bars) and pair fed, ACSF treated male MKR mice (hatched bars). A. Glucose infusion rate (GIR) during the clamp, B.
peripheral glucose disappearance rate (Rd), hepatic glucose production (GP) under basal conditions (C) or hyperinsulinemia (D). All data presenteda s
means 6 SEM. N=5–6/group. Different superscript letters indicate significant differences at p,0.05.
doi:10.1371/journal.pone.0017058.g005
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(Figure 6A,B).
Discussion
The present results demonstrate that central leptin improves
glucose homeostasis in the non-obese Type 2 diabetic MKR mouse.
Third intracerebroventricular administration of leptin markedly
increased whole body glucose tolerance as well as glucose disposal
during hyperinsulinemic euglycemic clamps. We conjectured that
brain leptin acted via the liver rather than the skeletal muscle to
produce these effects, because muscle insulin- and IGF-1- induced
glucose uptake into muscle is abrogated by the genetically
engineered dnIGF-1R in MKR muscle [1]). Consistent with this
idea, intracerebroventricular and hypothalamic leptin administra-
tion alters hepatic glucose fluxes and glucose production [6,7], and
such alterations are mediated in part via the intact hepatic vagus
nerve [10]. Consequently, we evaluated the degree to which hepatic
branch vagotomy affected the ability of central leptin to improve
glucose homeostasis. Vagotomy modestly reversed the improve-
ment in glucose tolerance in central leptin treated animals, but the
overall area under the curve was not significantly changed,
suggesting that the consequences of leptin’s actions on other tissues
may be playing a more important role in determining this effect.
One possible mechanism is the reduction of substrates reaching the
liver, such as fatty acids.
Accordingly, we report that adiposity, plasma TG and FFA
were decreased and fat oxidation and oxygen consumption were
increased in leptin treated animals relative to ACSF vehicle treated
controls. These data suggest a direct neural action of leptin on
lipid metabolism that is consistent with results from previous
studies. Leptin activates sympathetic nerves supplying white
adipose tissue via a central neural pathway to increase plasma
glycerol and free fatty acid levels [12]. Furthermore, mediobasal
hypothalamic administration of leptin decreases white adipose
tissue (WAT) lipogenesis, and this effect is blocked by sympathetic
denervation, supporting the existence of a hypothalamic WAT
circuit mediating lipid metabolism [5]. In MKR mice, increased
b3 adrenergic stimulation, targeting adipose tissue, improves
whole body glucose homeostasis and hepatic insulin sensitivity,
accompanied by reduced adiposity and increased fat oxidation [3].
Here we report that central leptin also improves hepatic glucose
production and hepatic insulin sensitivity during clamps, again in
parallel with reduced adiposity and increased fat oxidation. Thus,
some of the present improvement in overall glucose homeostasis
we observed may be secondary to leptin-induced reductions in
adiposity in white adipose tissue, as supported by the inability to
identify and retrieve epididymal, inguinal or omental white
adipose tissue in animals after leptin treatment.
The increases in fat oxidation and reductions in plasma free
fatty acids and TG following central leptin administration were
accompanied by an increase in oxygen consumption. This
occurred in spite of a significant reduction in total locomotor
activity. The effect of ICV leptin on locomotor activity in the
MKR mice contrasts the effect seen in other mouse models [13]
and maybe specific to the MKR mice. Future studies should
include wild-type control mice using the same FVBn background
to address this discrepancy. On the other hand, part of the
apparent discrepancy between increased oxygen consumption and
reduced locomoter activity following ICV leptin, may be due to
the ability of central leptin to increase sympathetic outflow to
brown adipose tissue, thereby increasing thermogenesis [14].
Alternatively, skeletal muscle may be a metabolic target of central
leptin action in the MKR mouse. Consistent with this suggestion,
we found that hyperinsulinemic-euglycemic clamps in MKR mice
receiving central leptin displayed a marked increase in the rate of
disappearance of glucose. Intracerebroventricular and parenchy-
mal hypothalamic administration of leptin have been demonstrat-
ed to increase skeletal muscle glucose metabolism, glucose uptake
and fat oxidation, and these effects are blocked by either surgical
denervation or by application of chemical agents that block
sympathetic neural outflow to skeletal muscle [8,9,15,16,17].
These effects of central leptin appear to be mediated by brain
melanocortin receptors, as central administration of the melano-
cortin 3/4 receptor antagonist SHU9119 blocks the ability of
ventromedial hypothalamic (VMH) leptin to increase skeletal
muscle glucose uptake, while ICV or direct VMH injection of
melanoocortin receptor agonists increase uptake [18]. Since the
present study did not include experiments to test these effects
directly, our conclusions must remain speculative and await
confirmation in future studies.
Figure 6. Glucose tolerance in leptin-treated MKR mice with or
without hepatic vagotomy. Selective hepatic branch vagotomy
(VGX) partially reversed the ability of two week third intracerebroven-
tricular leptin treatment to improve glucose tolerance in male MKR
mice, relative to artificial cerebrospinal fluid (ACSF) vehicle treated
controls. SHAM = sham surgical treatment. A. Intraperitoneal glucose
tolerance (ipGTT, 2 g/kg), * p,0.05, B. Area under the curve (AUC)
during ipGTT. All data presented as means 6 SEM, N=6–7/group.
Different superscript letters indicate significant differences at p, 0.05.
*p ,0.05.
doi:10.1371/journal.pone.0017058.g006
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leptin in STZ-induced Type 1 diabetic rodents [19,20]. Both
peripheral and ICV administered leptin improved the hypergly-
cemic state, despite the absence of circulating insulin. These data
as well as those from the present study, strongly suggest that the
effects of leptin (whether via the hypothalamus or directly on
peripheral tissues) on glucose homeostasis are unique and require
further investigation.
In summary, we have shown that central leptin is an effective
anti-diabetic therapy in a non-obese model of type 2 diabetes.
Current evidence supports the suggestion that its beneficial
metabolic effects in this model rely on distinct neural linkages
between central leptin receptors and adipose tissue, liver and
skeletal muscle.
‘‘All animal protocols were approved by the IACUC commit-
tees of the Mount Sinai School of Medicine and the Albert
Einstein College of Medicine of Yeshiva University.’’ Protocol
Einstein #20090402 approval date 7/13/2009. Protocol Mt Sinai
# IACUC MKR metabolism 05-1274.
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